Autolus Therapeutics (NASDAQ:AUTL) Trading Up 16.1% – What’s Next?

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) shot up 16.1% on Monday . The company traded as high as $1.8350 and last traded at $1.8920. 873,891 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 1,728,245 shares. The stock had previously closed at $1.63.

Analyst Ratings Changes

A number of research analysts have issued reports on AUTL shares. Weiss Ratings lowered shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Mizuho dropped their price target on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Truist Financial raised Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Finally, HC Wainwright increased their price objective on Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.75.

Autolus Therapeutics Price Performance

The firm’s fifty day moving average is $1.48 and its two-hundred day moving average is $1.51. The firm has a market cap of $499.01 million, a price-to-earnings ratio of -1.72 and a beta of 1.93.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, May 14th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The firm had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $26.27 million. On average, equities analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marex Group plc acquired a new stake in Autolus Therapeutics in the second quarter worth approximately $28,000. Independent Advisor Alliance acquired a new position in shares of Autolus Therapeutics during the 4th quarter valued at $28,000. SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter worth $43,000. Waverly Advisors LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter worth $37,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Autolus Therapeutics in the third quarter valued at $46,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.